The trial is structured as a non-randomised, open-label study in patients with relapsed, resistant or metastatic HPV-related ...

Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major kidney outcomes and major ...

The ASI drug class potentially fills an unmet need in the CKD space. Credit: crystal light via Shutterstock. On 15 November ...

Spirovant has announced the commencement of its Phase I/II study with the first patient receiving a dose of SP-101 to treat ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...